- EQS-DD: MorphoSys AG: Dr. Marc Cluzel, buy
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
- EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
- EQS-DD: MorphoSys AG: Charlotte Lohmann, Allocation of 157 shares as part of her remuneration as member of the Managing Board (Performance Share Plan 2019) (issuer's own shares)
- EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
- EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
- EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
- EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
- EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
MorphoSys AG (MOR:STU) closed at 25.40, -0.78% below its 52-week high of 25.60, set on Jun 05, 2023.
11.82Dec 16 202225.60Jun 05 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||872.23m EUR|
|EPS (TTM)||-2.14 |
Data delayed at least 15 minutes, as of Jun 05 2023.